- Annual Meeting
Chairman and CEO: Jeffrey Aronin
Paragon Biosciences is a Chicago-based incubator and investor that builds and grows leading biotechnology companies. At Paragon, we do things differently. We begin with patients suffering from debilitating diseases with no effective treatment. We then identify novel science to address the underlying cause of the disease. And ultimately, we invest in building innovative biotech companies completely focused on important unmet needs. We help people live longer, healthier lives.
A strong track record of important drug approvals
The Paragon team has succeeded in getting 13 new drug approvals from the U.S. Food and Drug Administration over the past decade, a success rate on par or higher than Big Pharma during the same time frame. Our approach of rational drug development guides us as we identify serious unmet patient needs, advance innovative science and build great companies to get medicines approved.
A portfolio of innovative, patient-focused biotech companies
More than 6,000 diseases have no treatment available and many more disease currently lack novel options. Our focus is on those opportunities to bring innovative medicine to those who truly need it the most. We attract top talent and blue-chip investors as we build dynamic companies to accelerate science.
Focus: Sleep and central nervous system disorders.
Focus: Alzheimer’s disease therapeutics to improve patient outcomes and quality of life.
Focus: Dermatological treatments to address significant unmet medical needs.
Focus: Complex treatments in rare genetic oncology-related disorders.
Chairman and CEO